Spot Biosystems emerged from stealth with $40 million in venture financing to pioneer a novel non-viral extracellular vesicle (EV) delivery platform for genetic medicines.
The California-based company has landmark preclinical research published in Nature Biomedical Engineering and an ongoing first-in-human (FIH) clinical trial with early results showing potential for successful translation to patients with Duchenne muscular dystrophy (DMD).
Spot has developed an EV-based gene therapy platform that delivers full-length dystrophin-encoding nucleic acids to skeletal muscle via engineered extracellular vesicles administered intravenously. Unlike viral vectors — which are constrained by small cargo capacity, a practical one-dose lifetime limit due to capsid immune responses, and the risk of viral toxicity — EV gene therapy is nonviral, supports repeat dosing, and can carry large therapeutic payloads, making it well suited for DMD and other chronic genetic diseases requiring long-term protein supplementation.
Spot plans to continue generating and reporting on its FIH data through an investigator-initiated trial (IIT) at Shanghai Children's Medical Center, with the goal of using those results to inform and accelerate a future U.S. regulatory pathway.
The company is backed by leading investors including LDV Partners, IDG Capital, Advantech Capital, Tiger Jade Capital, Shanda Ventures, the Stanford StartX fund and Saltagen Ventures.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!